Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Background Immune checkpoint inhibitors (ICI) have emerged as a front-line therapy for a variety of solid tumors. With the widespread use of these agents, immune-associated toxicities are increasingly being recognized, including fatal myocarditis. There are limited data on the outcomes and prognosti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Edward J Spangenthal, Igor Puzanov, Marc S Ernstoff, Pankit Vachhani, Fumito Ito, Ankita Kapoor, Benjamin Switzer, Poornima Subramanian, Yan V Yatsynovich, David M Jacobs, Maya R Chilbert, Umesh C Sharma, Steven G Feuerstein, Filip Stefanovic, Mark D Hicar, Anne B Curtis, Grace K Dy, Brian J Page, Nikhil Agrawal, Arjun Khunger, Alexander Hattoum, Jerome J Schentag
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/26e58c0f16aa4f4d82e356fda713f180
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/26e58c0f16aa4f4d82e356fda713f180

Ejemplares similares